Study of EVOLVE104 for advanced bladder and squamous cell cancers
Part of Cancer, Digestive system, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an experimental drug called EVOLVE104 for people with advanced bladder cancer or certain types of squamous cell cancers. It aims to see if the drug is safe and if it can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced bladder cancer or squamous cell cancer of the lung, esophagus, skin, or anogenital area that has spread or cannot be removed by surgery.
- Your cancer must have gotten worse during or after standard treatment.
- You need to have tumor that can be measured on a CT scan or MRI.
- You must be able to do most daily activities on your own (ECOG score 0 or 1).
- You must be willing to provide a tumor tissue sample, either from a past biopsy or a new one.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
This study tests adding new treatments to a standard therapy (enfortumab vedotin and pembrolizumab) for people with advanced bladder cancer that hasn't been treated before. It aims to find out if these combinations are safe and work better.
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
This Phase 2 study tests how well pembrolizumab and an antibody-drug medicine (EV) given with bladder radiation work for non-metastatic bladder cancer that is mostly urothelial. It may help some people control the cancer without it spreading to other organs.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.